L’interprétation et la classification des variants somatiques demeurent un challenge alors que le nombre de gènes testés continue d’augmenter faisant...
The study of the COVID-19 pandemic often involves sequencing the SARS-CoV-2 virus using Illumina, Nanopore, IonTorrent and Sanger technologies alone or in combination. Depending on the sampling and library preparation method used, this can involve metatranscriptomic data of varying viral content. In this webinar tutorial, you will learn about: Best practices for ...
QIAGEN Ingenuity Pathway Analysis (IPA) reveals the hidden upstream drivers and downstream outcomes in your toxicogenomics datasets. Put those results into context using Analysis Match with over 50,000 pre-analyzed datasets for human, mouse and rat. Explain the causes and effects in your studies so you can generate hypotheses to develop better drugs, biomarkers and mo...
Join our webinar to discover a scalable workflow for SARS-CoV-2 whole genome sequencing to accelerate detection of variants such as B.1.1.7 and B.1.351. In this new webinar, we will describe how QIAGEN’s QIAseq SARS-CoV-2 integrated workflow combines QIAseq chemistries and CLC Genomics Analysis software to deliver a scalable, high-performance solution for sequencing...
Identifying and studying actionable variants is of great interest to many investigators. In this webinar, COSMIC, HGMD and QIAGEN database will be introduced for annotation and investigation of both somatic and germline variants. Attendees will learn how to use QIAGEN Clinical Insight Interpret Translational (QCI-IT) to identify key actionable variants from whole geno...
In this webinar presented by Rockefeller University, Danbury Hospital and QDI, we present a unique case study of a treatment-naïve patient with aggressive metastatic uLMS who has experienced long-term survival. Using whole exome sequencing (WES), we analyzed 5 tumors to identify mechanisms of uLMS tumor growth and metastasis in this patient. Attendees of this webi...
Learn about a new database that helps you accelerate cancer drug development. This is the ONE tool that all translational research programs need to accelerate cancer drug R&D. Free trials offered to all attendees. Webinar Abstract The paradigm of predictive biomarkers of therapeutic responses to drug intervention has dramatically transformed cancer...
Join Dr. Marie-Laure Yaspo, Co-Founder and Chief Scientific Officer of Alacris Theranostics, as she discusses the development, application, and analysis of the Comprehensive Molecular Tumor Analysis (CMTA) test for cancer patients. Precision oncology approaches have made great strides harnessing individual tumor mutation profiles to guide targeted therapy choic...
